R&D Pipeline -- IND-enabling activities for a PSMA-targeted ADC are on track for completion by year-end, further expanding the development portfolio.

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCCData from a Phase ...

Agreement encompasses deconversion, fabrication, packaging, and transportation services for Integral Molten Salt Reactor (IMSR) fuel production, ...

CEO Treace stated, "we are not growing our line the way we anticipated for the year," while also noting case volume growth in ...

Q3 2025 Earnings Call November 6, 2025 4:30 PM ESTCompany ParticipantsTrip TaylorJohn Treace - Founder, Chairman ...

Q3 2025 Earnings Call Transcript November 5, 2025 Quantum-Si incorporated misses on earnings expectations. Reported EPS is ...

Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent ...

Q3 2025 Earnings Call October 29, 2025 4:25 PM EDTCompany ParticipantsStan Finkelstein - Head of Investor RelationsMike Slessor ...

Q3 2025 Earnings Call Transcript November 7, 2025 DoubleVerify Holdings, Inc. misses on earnings expectations. Reported EPS ...

AdvanSix Inc. (NYSE: ASIX) Q3 2025 Earnings Call Transcript November 7, 2025 AdvanSix Inc. misses on earnings expectations.

Acknowledging the need for a specialized facility where people suffering a mental health or substance use crisis can get ...